medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2024, Number 3

<< Back

Arch Med Fam 2024; 26 (3)

Neurological Sequelae Post Covid-19: Bibliographic Review

Fernández OMÁ, Sánchez MI, Chávez CA

Language: Spanish
References: 44
Page: 171-175
PDF size: 177.08 Kb.


ABSTRACT

Around 10 to 20% of patients who had Covid-19 developed long Covid; however, many authors have reported a higher prevalence , especially in survivors of severe pneumonia. Neurological symptoms are mainly characterized by headache, delirium, vertigo, alterations in cognition, concentration problems, short-term memory deficit, decrease in attention, language and praxis, among others syptoms. There is evidence that the SARS-CoV-2 virus triggers inflammatory processes that accelerate neurological deterioration due to the accumulation of tau protein and fibrillar B-amyloid in neurons, which could cause the cognitive deterioration that has been reported and that also It is present in Alzheimer’s Disease. It is a priority that the family doctor can make a timely diagnosis of these sequelae and initiate appropriate management, including referral to the neurologist of affected patients, seeking to delay the evolution of neurological damage.


REFERENCES

  1. Pan American Health Organization (PAHO). Informesde situación de la COVID-19. 2023 [Citado 27 Dic 2023].Disponible en: https://www.paho.org/es/informes-situacion-covid-19.

  2. Organización Mundial de la Salud (OMS). Enfermedadpor coronavirus (COVID-19): afección posteriora la COVID-19. 2023 [Citado 27 Dic 2023]. Disponibleen: www.who.int/es/news-room/questions-andanswers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.

  3. Correa EM,Vallespín GT. COVID persistente. Elementosbásicos para el médico de atención primaria. FMC-FormaciónMédica Continuada en Atención Primaria [Internet].2022;29(9):481-489. Disponible en: https://doi.org/10.1016/j.fmc.2022.02.015

  4. National Institute for Health and Care Excellence(NICE). COVID-19 rapid guideline: managing the longtermeffects of COVID-19. 2020 [Citado 26 Dic 2023].Disponible en: https://www.nice.org.uk/guidance/ng188.

  5. Zhou H, Lu S, Chen J, Wei N, Wang D, Lyu H, Shi C, HuS. The landscape of cognitive function in recoveredCOVID-19 patients. Journal of psychiatric research [Internet].2020;129:98-102. Disponible en: https://doi.org/10.1016/j.jpsychires.2020.06.022.

  6. Fernández-Ortega MÁ, Ponce-Rosas ER, Muñiz-SalinasDA, Rodríguez-Mendoza O, Chávez PN, Sánchez-PozosV, Dávila-Mendoza R, & Barrell AE. Cognitive dysfunction,diabetes mellitus 2 and arterial hypertension: sequelaeup to one year of COVID-19. Travel Medicine andInfectious Disease [Internet]. 2023;52:102553. Disponibleen: https://doi.org/10.1016/j.tmaid.2023.102553.

  7. Wynberg E, van-Willigen HDG, Dijkstra M, Boyd A,Kootstra NA, van den-Aardweg JG, van Gils MJ, MatserA, de-Wit MR, Leenstra T, de Bree G, de Jong MD,Prins M. Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months AfterIllness Onset. Clinical Infectious Diseases [Internet].2021;75(1):482-490. Disponible en: https://doi.org/10.1093/cid/ciab759.

  8. Thompson EJ, Williams DM, Walker AJ, Mitchell RE,Niedzwiedz CL, Yang TC, Huggins CF, et al. Risk factorsfor long COVID: analyses of 10 longitudinal studies andelectronic health records in the UK. medRxiv [Internet].2021. Disponible en: https://doi.org/10.1101/2021.06.24.21259277.

  9. Premraj L, Kannapadi NV, Briggs J, Seal SM, BattagliniD, Fanning J, Suen J, Robba C, Fraser J, Cho SM.Mid and long-term neurological and neuropsychiatricmanifestations of post-COVID-19 syndrome: A meta-analysis. Journal of the Neurological Science [Internet].2022;434:120162.Disponible en: https://doi.org/10.1016/j.jns.2022.120162

  10. Shin T, Kim JT, Ahn M, Moon C. Olfactory Dysfunctionin CNS Neuroimmunological Disorders: A review. MolecularNeurobiology [Internet].2018;56(5):3714-21.Disponible en: https://doi.org/10.1007/s12035-018-1341-0

  11. Yao Y, Wang H, Liu Z. Expression of ACE2 in airways:Implication for COVID 19 risk and disease managementin patients with chronic inflammatory respiratory diseases.Clinical & Experimental Allergy [Internet].2020;50(12):1313-1324. Disponible en: https://doi.org/10.1111/cea.13746.

  12. Jami G, Ataee M, Esmaeili V, Chamani S, Rezaei A, NaghizadehA. Characterization of the angiotensin-convertingenzyme 2 (ACE2), the main receptor for theSARS-CoV-2 virus. American Journal of Clinical and ExperimentalImmunology [Internet]. 2023;12(3):24-44.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349303/

  13. Chen R, Wang K, Yu J, Howard D, French L, Chen Z,Wen C, & Xu Z. The Spatial and Cell-Type Distributionof SARS-CoV-2 Receptor ACE2 in the humanand Mouse Brains. Frontiers in Neurology [Internet].2021;11:573095. Disponible en: https://doi.org/10.3389/fneur.2020.573095.

  14. Nalbandian A, Sehgal K, Gupta A, Madhavan MV,McGroder C, Stevens JS, Cook JR, Nordvig AS, et al.Post-acute COVID-19 syndrome. Nature Medicine [Internet].2021;27(4):601-615. Disponible en: https://doi.org/10.1038/s41591-021-01283-z.

  15. Tejera D, Mercan D, Sanchez Caro JM, Hanan M, GreenbergD, Soreq H, Latz E, Golenbock D, Heneka MT.Systemic inflammation impairs microglial Aβ clearancethrough NLRP3 inflammasome. The EMBO Journal[Internet].2019;38(17).Disponible en: https://doi.org/10.15252/embj.2018101064.

  16. Ritchie K, Chan D, Watermeyer T. The cognitive consequencesof the COVID-19 epidemic: collateral damage?.Brain Communications [Internet]. 2020;2(2).Disponible en: https://doi.org/10.1093/braincomms/fcaa069.

  17. Sy M, Kitazawa M, Medeiros R, Cheng D, Lane TE,LaFerla FM. Inflammation induced by infectionpotentiates TAU pathological features in transgenicmice. American Journal of Pathology [Internet].2011;178(6):2811-2822. Disponible en: https://doi.org/10.1016/j.ajpath.2011.02.012.

  18. Sartori AC, Vance DE, Slater LZ, Crowe M. The impactof inflammation on cognitive function in olderadults. Journal of Neuroscience Nursing [Internet].2012;44(4):206-217. Disponible en: https://doi.org/10.1097/jnn.0b013e3182527690.

  19. Pirker-Kees A, Platho-Elwischger K, Hafner S, RedlichK, Baumgartner C. Hyposmia is associated withreduced cognitive function in COVID-19: first preliminaryresults. Dementia and geriatric cognitive disorders[Internet]. 2021;50(1):68-73. Disponible en:DOI: 10.1159/000515575.

  20. Castillo-Álvarez F, Fernández-Infante E, Campos MS, &García-Mozún B. Sintomatología neuropsiquiátrica enel síndrome post-COVID. Propuesta de manejo y derivacióndesde atención primaria. Medicina de FamiliaSEMERGEN [Internet].2022;48(4):263-274. Disponibleen: https://doi.org/10.1016/j.semerg.2021.09.012.

  21. Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatricand neuropsychiatric sequelae of COVID-19 – Asystematic review. Brain, Behavior, and Immunity [Internet].2021;97:328-348. Disponible en: doi10.1016/j.bbi.2021.07.018.

  22. Vanderlind WM, Rabinovitz BB, Miao IY, Oberlin LE,Bueno-Castellano C, Fridman C, Jaywant A, KanellopoulosD. A systematic review of neuropsychologicaland psychiatric sequalae of COVID-19: implicationsfor treatment. Current Opinion in Psychiatry [Internet].2021;34(4):420-433. Disponible en: DOI: 10.1097/YCO.0000000000000713.

  23. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, GriffantiL, Alfaro-Almagro F, Okell T, et al. Medium-termeffects of SARS-CoV-2 infection on multiple vital organs,exercise capacity, cognition, quality of life andmental health, post-hospital discharge. Eclinical-Medicine [Internet]. 2021;31:100683. Disponible en:doi: 10.1016/j.eclinm.2020.100683.

  24. Ferrucci R, Dini M, Rosci C, Capozza A, Groppo E, ReitanoMR, Allocco E, Poletti B, Brugnera A, Bai F, MontiA, Ticozzi N, Silani V, Centanni S, D’Arminio-MonforteA, Tagliabue L, & Priori A. One-year cognitive follow-upof COVID-19 hospitalized patients. European Journal ofNeurology [Internet]. 2022;29(7):2006-2014. Disponibleen: https://doi.org/10.1111/ene.15324.

  25. Crivelli L, Palmer K, Calandri I, Guekht A, Beghi E,Carroll W, Frontera J, García-Azorín D, Westenberg E,Winkler AS, Mangialasche F, Allegri RF, & KivipeltoM. Changes in cognitive functioning after COVID-19:A systematic review and meta-analysis. Alzheimer’s& Dementia, The Journal of the Alzheimer´s Association[Internet]. 2022;18(5):1047-1066.Disponible en:https://doi.org/10.1002/alz.12644.

  26. De la Rosa-Carrillo D, Castillo-Villegas D, Gutiérrez-PereyraF. Seguimiento del paciente post Covid. En BarreiroE, editor. Fisiopatología de la covid-19 en diferentesórganos y sistemas [Elsevier] 2022.p.169-182.

  27. Gutierrez-Robledo LM, García-Peña MDC,Roa-RojasPA, Martínez-Ruiz A. La Enfermedad de Alzheimer yotras demencias como problema nacional de salud.Academia Nacional de Medicina de México. México;2017 [Citado 26 Dic 2023]. Disponible en: https://www.anmm.org.mx/publicaciones/ultimas_publicaciones/ANM-ALZHEIMER.pdf

  28. Peterson RC, Graff-Radford J. Enfermedad de Alzheimery otras demencias. EnBradley & Daroff, NeurologíaClínica [Elsevier]. p1452-1455.

  29. Delgado C, Araneda A, Behrens MI. Validación del instrumentoMontreal Cognitive Assessment en españolen adultos mayores de 60 años. Neurología [Internet].2019;34(6):376-385. Disponible en:http://doi.org/10.1016/j.nrl.2017.01.013.

  30. Aguilar-Navarro SG, Mimenza-Alvarado AJ, Palacios-García AA, Samudio-Cruz A, Gutiérrez-GutiérrezLA, Ávila-Funes JA. Validez y confiabilidad del MoCA(Montreal Cognitive Assessment) para el tamizaje deldeterioro cognoscitivo en México. Revista Colombianade Psiquiatría [Internet]. 2018;47(4):237-243. Disponibleen: https://doi.org/10.1016/j.rcp.2017.05.003.

  31. Arun Raj, A & Zulfi H. Systematic review of EEG findingsin 617 patients diagnosed with COVID-19. Seizure: EuropeanJournal of epilepsy [internet].2020;83:234-241.Disponible en:https://doi.org/10.1016/j.seizure.2020.10.014.

  32. Cecchetti G, Agosta F, Canu E, Basaia S, Barbieri A, CardamoneR, et al. Cognitive, EEG, and MRI features ofCOVID-19 survivors: a 10-month study. Journal of Neurology[Internet]. 2022; 269(7):3400-3412. Disponibleen:https://doi.org/10.1007/s00415-022-11047-5.

  33. Atri A. The Alzheimer’s Disease Clinical Spectrum:Diagnosis and Management. The Medical clinics ofNorth America [Internet].2019;103(2):263–293.Disponibleen: 10.1016/j.mcna.2018.10.009

  34. Shen L, Ji HF. Vitamin D deficiency is associated withincreased risk of Alzheimer’s disease and dementia:evidence from meta-analysis. Nutrition journal [Internet].2015;14(76). Disponible en: 10.1186/s12937-015-0063-7

  35. Kouloutbani K, Karteroliotis K, Politis A. The effect ofphysical activity on dementia. Psychiatriki QuarterlyJournal of the Hellenic Psychiatric Association [Internet].2019;30(2):142-155. Disponible en: 10.22365/jpsych.2019.302.142

  36. Bagheri F, Rashedi V. Simultaneous exposure tonoise and carbon monoxide increases the risk of Alzheimer’sdisease: a literature review. Medical gasresearch [Internet]. 2020;10(2):85-90. Disponible en:10.4103/2045-9912.285562

  37. Shenker, J. I., & Singh, G. Sleep and Dementia. Missourimedicine. 2017;114(4): 311–315. Disponibleen: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140093/

  38. Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-GuerreroA, Woo VL, Kumar S, Colman S, Pollock BG,Mulsant BH, & Rajji TK. Sequential drug treatmentalgorithm for agitation and aggression in Alzheimer’sand mixed dementia. Journal of psychopharmacology[Internet]. 2018;32(5):509-523. Disponible en:10.1177/0269881117744996

  39. Spijker A, Vernooij-Dassen M, Vasse E, Adang E, WollersheimH, Grol R, Verhey F. Effectiveness of nonpharmacologicalinterventions in delaying the institutionalizationof patients with dementia: a meta-analysis.Journal of the American Geriatrics Society [Internet].2008;56(6):1116-1128. Disponible en: 10.1111/j.1532-5415.2008.01705.x

  40. Boix V, Merino E. Síndrome post-COVID, el desafío continúa.Medicina Clínica [Internet].2022;158(4):178-180.Disponible en: https://doi.org/10.1016/j.medcli.2021.10.002

  41. Instituto Mexicano del Seguro Social (IMSS). Diagnósticoy Tratamiento de la Enfermedad de Alzheimer.Guía de Evidencias y Recomendaciones: Guía de PrácticaClínica. México. 2017 [Citado 26 Dic 2023]. Disponibleen: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/393GER.pdf.

  42. Bombón-Albán PE, Suárez-Salazar JV. Manifestacionescognitivas y neuropsiquiátricas de COVID-19 enel Adulto Mayor con y sin demencia: Revisión de laliteratura. Revista de Neuro-Psiquiatría [Internet].2022;85(2):117-126. Disponible en: https://doi.org/10.20453/rnp.v85i2.4229.

  43. Siu KL, Yuen KS, Castano-Rodriguez C, Ye ZW, YeungML, Fung SY, Yuan S, Chan CP, Yuen KY, Enjuanes L,& Jin DY. Severe acute respiratory syndrome CoronavirusORF3a protein activates the NLRP3 inflammasomeby promoting TRAF3-dependent ubiquitination ofASC. The FASEB Journal [Internet]. 2019;33(8):8865-8877. Disponible en: https://doi.org/10.1096/fj.201802418R.

  44. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, SorondF. Relation of C-reactive protein to stroke, cognitivedisorders, and depression in the general population:systematic review and meta-analysis. The Lancet Neurology[Internet]. 2005;4(6):371-80. Disponible en:DOI: 10.1016/S1474-4422(05)70099-5.




2020     |     www.medigraphic.com